Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical research trials and Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer. Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "M" Clinical Trials Conditions > Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer



Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

For Condition: Cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have leptomeningeal cancer.
Details: OBJECTIVES: - Define the clinical toxicities of intrathecal iodine I 131 monoclonal antibody 3F8 (I-3F8) in patients with GD2 positive leptomeningeal neoplasms. - Determine whether I-3F8 can detect GD2 positive leptomeningeal tumors. - Measure the cerebrospinal fluid (CSF) levels and serum pharmacokinetics of I-3F8 in these patients. OUTLINE: This is a dose escalation study. Patients receive a single injection of intraventricular or intrathecal iodine I 131 monoclonal antibody 3F8. Patients without objective disease progression and no grade 3 or 4 toxicity 6 weeks after the first dose may receive a second injection. Cohorts of at least 3 patients are entered at escalating doses of I-3F8. If grade 3 or worse toxicity occurs in 1 or more of 3 patients at a given dose level, then 3 additional patients are accrued at that level. If 2 or more of 6 patients at a given dose level experience grade 3 or worse toxicity, then that dose is declared the maximum tolerated dose (MTD). Patients are followed weekly for 4 weeks. PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study over 2-3 years.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 3 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed malignancy expressing GD2, including, but not limited to: - Medulloblastoma/primitive neuroectodermal tumor of the CNS - Malignant glioma - Neuroblastoma - Retinoblastoma - Ependymoma - Sarcoma - Melanoma - Small cell lung carcinoma - Other tumor types must have GD2 expression confirmed by immunohistochemical staining - Cerebrospinal fluid or leptomeningeal disease that is refractory to conventional therapy or for which no conventional therapy exists - Prior measurable human anti-mouse monoclonal antibody titer allowed PATIENT CHARACTERISTICS: Age: - 3 and over Performance status: - Not specified Life expectancy: - At least 2 months Hematopoietic: - Absolute neutrophil count greater than 1,000/mm^3 - Platelet count greater than 50,000/mm^3 Hepatic: - Bilirubin less than 3 mg/dL Renal: - Creatinine less than 2 mg/dL - Blood urea nitrogen less than 30 mg/dL Other: - May have active malignancy outside the central nervous system - No obstructive hydrocephalus - No CNS grade 3 or 4 toxicity as a consequence of prior treatments - No life threatening infection PRIOR CONCURRENT THERAPY: Biologic therapy: - Prior monoclonal antibody treatment allowed Chemotherapy: - Prior chemotherapy allowed - Must have recovered from all hematopoietic and neurologic side effects of prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - Prior radiotherapy allowed - At least 6 weeks since prior cranial or spinal irradiation Surgery: - Not specified
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
KimKramer,  Study Chair,  Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City,  New York,  10021
United States
Recruiting Kim  Kramer 212-639-6410


Additional Information:
Study ID Numbers:  CDR0000065607;  MSKCC-97021,NCI-G97-1267
Study Start Date: 
Record last reviewed: November 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003022

Other Cancer Studies:
1. Natrecor in Pulmonary Hypertension

2. Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

3. Pesticides--Health Fertility and Reproductive Risk

4. Epothilone (ixabepilone) plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer

5. A Phase I Study of Infusional Paclitaxel with the P-Glycoprotein Antagonist PSC 833

Related Studies:

Other Cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Modify your Search

  Other Cancer Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103